» Articles » PMID: 33079278

SDF-1 Mediates Mesenchymal Stem Cell Recruitment and Migration Via the SDF-1/CXCR4 Axis in Bone Defect

Overview
Specialty Endocrinology
Date 2020 Oct 20
PMID 33079278
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Recent studies have indicated the potential of stem cell therapy in combination with cytokines to restore the bone repair via migration and homing of stem cells to the defected area. The present study aimed to investigate the mobilization and recruitment of mesenchymal stem cells (MSCs) in response to SDF-1.

Materials And Methods: Herein, the knockout rat model of the bone defect (BD) was treated with the induced membrane technique. Then, wild type Wistar rats and SDF-1-knockout rats were selected for the establishment of BD-induced membrane (BD-IM) models and bone-graft (BG) models. The number of MSCs was evaluated by flow cytometry, along with the expression pattern of the SDF-1/CXCR4 axis as well as osteogenic factors was identified by RT-qPCR and Western blot analyses. Finally, the MSC migration ability was assessed by the Transwell assay.

Results: Our data illustrated that in the induced membrane tissues, the number of MSCs among the BD-IM modeled rats was increased, whereas, a lower number was documented among BG modeled rats. Besides, we found that lentivirus-mediated over-expression of SDF-1 in BG modeled rats could activate the SDF-1/CXCR4 axis, mobilize MSCs into the defect area, and up-regulate the osteogenic proteins.

Conclusions: Collectively, our study speculated that up-regulation of SDF-1 promotes the mobilization and migration of MSCs through the activation of the SDF-1/CXCR4 signal pathway.

Citing Articles

Advances in growth factor-containing 3D printed scaffolds in orthopedics.

Zhan L, Zhou Y, Liu R, Sun R, Li Y, Tian Y Biomed Eng Online. 2025; 24(1):14.

PMID: 39920740 PMC: 11806769. DOI: 10.1186/s12938-025-01346-z.


Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies.

Yuan Z, Zhang Y, He X, Wang X, Wang X, Ren S Theranostics. 2024; 14(17):6487-6515.

PMID: 39479455 PMC: 11519806. DOI: 10.7150/thno.102641.


Multifunctional extracellular vesicles and edaravone-loaded scaffolds for kidney tissue regeneration by activating GDNF/RET pathway.

Lee S, Park J, Rhim W, Lee E, Lee S, Kim J Nano Converg. 2024; 11(1):43.

PMID: 39460807 PMC: 11512987. DOI: 10.1186/s40580-024-00450-5.


Anti-Inflammatory and Anti-(Lymph)angiogenic Properties of an ABCB5+ Limbal Mesenchymal Stem Cell Population.

Meshko B, Volatier T, Mann J, Kluth M, Ganss C, Frank M Int J Mol Sci. 2024; 25(17).

PMID: 39273646 PMC: 11395824. DOI: 10.3390/ijms25179702.


Advances and clinical challenges of mesenchymal stem cell therapy.

Mei R, Wan Z, Yang C, Shen X, Wang R, Zhang H Front Immunol. 2024; 15:1421854.

PMID: 39100671 PMC: 11294097. DOI: 10.3389/fimmu.2024.1421854.


References
1.
Mehanna R, Nabil I, Attia N, Bary A, Razek K, Ahmed T . The Effect of Bone Marrow-Derived Mesenchymal Stem Cells and Their Conditioned Media Topically Delivered in Fibrin Glue on Chronic Wound Healing in Rats. Biomed Res Int. 2015; 2015:846062. PMC: 4508387. DOI: 10.1155/2015/846062. View

2.
Marquez-Curtis L, Janowska-Wieczorek A . Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. Biomed Res Int. 2014; 2013:561098. PMC: 3870125. DOI: 10.1155/2013/561098. View